1. Home
  2. Publications
  1. Home
  2. Publications

Filters

Research Groups

Core Facilities


Start date
End date

Cross-species graph-embedding unmasks the ageing microenvironment as a key determinant of pancreatic cancer malignant cell biology and therapy response

Authors: JA Henríquez, M Jihad, A Jassim, EG Lloyd, W Luo, JS Manansala, S Harish, ...
Research group: Biffi Group
E-pub date: 5 Feb 2026
Journal name:

MMP-cleavable linker platform for tumour-responsive homo- and heterobivalent antibody-drug conjugates.

Authors: AJ Counsell, SJ Walsh, N Ashman, M Park, FM Dannheim, TA King, T Wharton, J...
Research group: Carroll Group
E-pub date: 4 Feb 2026
Journal name: Chem Sci

Childhood brain tumors instruct cranial hematopoiesis and immunotolerance.

Authors: E Cooper, DA Posner, CYC Lee, L Hu, S Bonner, JT Taylor, O Baldwin, R Jimen...
Research group: Proteomics, Gilbertson Group, Mair Group, Halim Group
E-pub date: 1 Feb 2026
Journal name: Nat Genet

ApCAFs: spatial niches and therapeutic insights across cancers.

Authors: W Li, G Nsubuga, G Biffi
Research group: Biffi Group
E-pub date: 1 Feb 2026
Journal name: Trends Cancer

Author Correction: PHGDH heterogeneity potentiates cancer cell dissemination and metastasis.

Authors: M Rossi, P Altea-Manzano, M Demicco, G Doglioni, L Bornes, M Fukano, A Vand...
Research group: Hannon Group
E-pub date: 1 Feb 2026
Journal name: Nature

Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.

Authors:
Research group: Brenton Group, Narita Group
E-pub date: 1 Feb 2026
Journal name: Nat Aging

ICON8B: GCIG phase III randomised trial comparing first-line weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in high-risk stage III-IV epithelial ovarian cancer: final overall survival (OS) analysis

Authors: A Clamp, I Mcneish, D Radice, R Lord, A Michael, A Cook, R Agarwal, A Walth...
Research group: Brenton Group
E-pub date: 1 Feb 2026
Journal name: International Journal of Gynecological Cancer

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Authors: AM Vaquié, DR Shah, EES Brechbühl, M McNicholas, Z Xu, JH Stockley, L Mor...
Research group:
E-pub date: 1 Feb 2026
Journal name: Mol Oncol